The trading price of Cardiff Oncology Inc (NASDAQ:CRDF) closed lower on Monday, March 03, and closing at $3.82, -10.02% lower than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $6.42 and a 52-week low of $1.74. Over the past month, the stock has lost -3.90% in value.
Cardiff Oncology Inc, whose market valuation is $253.79 million at the time of this writing, is expected to release its quarterly earnings report in April. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -0.2 per share this quarter, however they have predicted annual earnings per share of -0.83 for current year and -0.98 for next year.
From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 333.33k.
On the technical side, indicators suggest CRDF has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned CRDF a recommendation rating is 1. Out of them, 0 rate it a Hold, while 1 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Cardiff Oncology Inc (CRDF) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that CRDF’s price is currently -12.68% off the SMA20 and -7.24% off the SMA50. The RSI metric on the 14-day chart is currently showing 43.39, and weekly volatility stands at 10.71%. When measured over the past 30 days, the indicator reaches 9.36%. Cardiff Oncology Inc (NASDAQ:CRDF)’s beta value is currently sitting at 1.73, while the Average True Range indicator is currently displaying 0.39.
To see how Cardiff Oncology Inc stock has been performing in comparison to its peers in the industry, here are the numbers: CRDF stock’s performance was -10.02% in the latest trading, and 109.62% in the past year.
An evaluation of the daily trading volume of Cardiff Oncology Inc (NASDAQ:CRDF) indicates that the 3-month average is 2.15 million.
Currently, records show that 66.52 million of the company’s shares remain outstanding. The insiders hold 10.13% of outstanding shares, whereas institutions hold 34.48%. However, since the stock’s price has seen -12.10% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
